Binary event trade with cash cushion: Q3 2026 earnings on Oct 27 (5 days away). 30.93% short interest sets up a squeeze on a beat, while $410M in cash + investments (vs $1.05B mkt cap) limits downside. Growth story credible on $225M+ federal contract awards disclosed since July, but still −74% from 52W high and Adj EBITDA still negative. Peer-driven SOTP = $2.80 (+28% base) with Bull $4.50 (+105%) if Q3 beats and squeeze triggers; Bear $1.50 (−32%) if guidance cut and dilution continues.
Forward EV/Revenue multiple SOTP on peer-driven multiples (SOUN 8.3x LTM, C3.ai ~4-5x fw). Core AI segment at 5x FY27E Rev (midpoint peer blend with lower-growth discount); Ask Sage GenAI at 10x (growth premium); net cash added at face value ($393M); backlog unfunded portion carried as probability-weighted option ($57.5M); explicit litigation ($20M) and dilution (-5%) adjustments. Implicit blended EV/Rev FY27E ≈ 5.3x, inside peer band. Our $2.80 FV is ~41% below the $4.76 analyst consensus because consensus assumes more aggressive multiple expansion and lower dilution; we apply a 40% implementation haircut on the gap. ⚠️ Not investment advice.
| Component | Assumption | USD/share |
|---|---|---|
| Core AI/Analytics EV | FY27E revenue $155M (ex-Ask Sage, +17% from guidance) × 5.0x EV/Rev (midway SOUN 8.3x and C3.ai 4x, discount for lower growth) = $775M EV / 479.5M sh | +1.62 |
| Ask Sage GenAI EV | FY27E revenue $25M × 10.0x EV/Rev (GenAI growth premium, ~1.2x SOUN LTM) = $250M EV / 479.5M sh | +0.52 |
| Net cash + investments | Cash + ST investments $409.8M − total debt $16.6M = $393.2M / 479.5M sh | +0.82 |
| Backlog option value | Unfunded $270M × 71% × 30% probability × 1.0x value capture = $57.5M / 479.5M sh | +0.12 |
| Litigation reserve | Expected class action settlement $20M base case (within class period 2022-2025 scope) / 479.5M sh | −0.04 |
| Dilution haircut (ATM) | 5% additional share issuance over 12 months (ATM funding) → −5% × $3.04 subtotal / sh | −0.24 |
| FV base case | 1.62 + 0.52 + 0.82 + 0.12 − 0.04 − 0.24 = $2.80 | ≈ $2.80 |
Insider activity (last 180 days): only ~$105K in true open-market sales (CFO Ricker $43K at $4.33 in May; director Hayes $62K at $4.10 in May). Rest is tax-withholding on RSU vesting (CFO Ricker $81K, CEO McAleenan $57K+$85K, GC Blankenship $24K+$32K). No single transaction above $500K materiality threshold. No open-market buying either. Director Lt. Gen. Sean Gainey added Aug 2026 (32,776 shares grant). CEO Kevin McAleenan (former Acting DHS Secretary) in position since Jan 2024.
| Item | FY2023 | FY2024 | FY2025 | FY2026E | Guidance 2026 |
|---|---|---|---|---|---|
| Revenue ($M) | 155.2 | 158.2 | 129.3 | ~150 | $135–$165 |
| Gross margin % | 25.0% | 27.8% | 28.4% | ~32% | Expanding |
| Adj EBITDA ($M) | −21.3 | −32.5 | −32.8 | ~−42 | Below prior |
| Net loss ($M) | −60.4 | −296.6 | −257.1 | ~−95 | Non-cash swings |
| Op cash flow ($M) | −39.8 | −43.9 | −57.7 | ~−75 | Runway intact |
| Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
| Revenue ($M) | 32.5 | 33.6 | 43.8 | 34.8 | 36.7 |
| Gross margin % | 25.0% | 27.1% | 31.8% | 34.5% | 32.8% |
| Adj EBITDA ($M) | −8.5 | −9.3 | −5.9 | −7.2 | −11.6 |
| End-of-period cash+inv ($M) | 125.4 | 152.1 | 50.1 | 385.5 | 409.8 |
Business model — AI/Decision Intelligence for Defense & National Security
Core AI/Analytics Services ~$95-105M FY26E (~65% rev) 🟢 recurring contracts Decision intelligence platforms, mission analytics, cyber. Multi-year prime contracts with DOD/intelligence. Primary driver of $225M+ new awards. GM target 30-35%. Ask Sage GenAI Platform ~$20-25M FY26E (~15% rev) 🟢 ramping GenAI for federal use (acquired 2026). FedRAMP-authorized. Highest-growth segment. Over 25 of recent contract wins are GenAI-specific. GM target 55-65%. Pangiam Computer Vision ~$25-35M FY26E (~20% rev) 🟡 to prove Biometric/identity, border security, aviation. Acquired 2024. Growth decelerating; margin profile under review. GM target 25-30%.
Customer concentration risk: Top 10 customers >70% of revenue, all federal agencies. Procurement cycles typically 6-18 months. Growth leverage comes from (a) new administration AI priorities (Trump DOD/DOGE AI build-out favorable), (b) backlog funding conversion (currently only 29% funded — the $192M unfunded portion represents option value if awarded), (c) Ask Sage attach to existing core contracts.
Legal, regulatory and risk analysis
SWOT analysis
- +$410M cash + investments = ~39% of market cap (4-5 year runway)
- +$225M+ in federal contract awards since July 2026 (DOD, CBP, FBI, NASA, DOE, VA)
- +FedRAMP-authorized GenAI (Ask Sage) differentiates in defense procurement
- +Backlog $269.6M, +9% YTD — 1.8x FY26E revenue coverage
- +Gross margin expanded to 32.8% Q2'26 from 25.0% Q2'25 (+780bps)
- −Adj EBITDA still negative (−$11.6M Q2'26) and worsening YoY
- −Share count up ~70% YoY — dilution has eroded per-share metrics
- −Only 13% revenue growth Q2'26 vs AI peers at 20-40%
- −Only 29% of backlog is funded — big gap vs sector norms (50%+)
- −Securities class action overhang (legacy derivative accounting)
- →Q3 2026 earnings on Oct 27 could trigger short squeeze (31% SI)
- →Ask Sage attach to core AI contracts drives higher ARPU and GM mix
- →Trump administration DOD/DOGE AI priorities multi-year revenue tailwind
- →Backlog funding ratio normalisation (+10pp = +$20M revenue upside)
- →Potential strategic acquisition premium given cash war chest
- !Further equity raise could trigger another dilution leg (20%+ in Bear)
- !Government shutdown or continuing resolution delays contract awards
- !Competition from Palantir, C3.ai, Scale AI in federal GenAI RFPs
- !Class action settlement higher than $25M would erode cash cushion
Summary by assessment area
- EV/Revenue FY27E ~3.7x vs SOUN 6.0x, C3.ai 3.8x — in line to discount
- SOTP $2.80 FV (+28% base) vs current $2.19
- Analyst consensus $4.76 implies 7-8x FY26E EV/Rev — aggressive
- Hard floor at $0.82 (net cash/sh) limits downside asymmetrically
- Three segments: Core AI (65%), Ask Sage GenAI (15%), Pangiam CV (20%)
- $225M+ contract awards disclosed Oct 13 validate pipeline
- 13% revenue growth Q2'26 — below peer AI, management guides 17% FY26
- GM expanding 25% → 33% as GenAI mix increases
- Still cash-burning, negative Adj EBITDA; breakeven in 2027-2028
- Dilution risk — share count up 70% YoY, ATM path probable
- 31% short interest = volatile; sharp drops possible on miss
- Class action legacy adds $15-25M settlement overhang
Sources: BigBear.ai Q2 2026 earnings release (businesswire.com), stock quotes financialcontent.com & Yahoo Finance, Quiver Quantitative short interest data (as of 2026-07-31), Fintel analyst consensus (as of 2026-08-28), SEC Form 4 filings (blarkad.com), Bronstein Gewirtz class action release (newsfilecorp.com), peer multiples from multiples.vc (SOUN) and tipranks (C3.ai, PLTR), Oct 13 contract awards summary (cryptobriefing.com). Market data — last verified close 2026-10-21: BBAI $2.19, market cap ~$1.05B, 52W range $2.12–$9.39, 479.49M shares outstanding. Short interest 30.93% as of 2026-07-31. Next earnings: 2026-10-27. This document is for informational purposes only and does not constitute financial or investment advice.